The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.405%)
Open: 38.00
High: 38.00
Low: 38.00
Prev. Close: 38.00
MIG1 Live PriceLast checked at -
Maven Income and Growth VCT is an Investment Trust

To achieve long term capital appreciation and generate maintainable levels of income for shareholders through investing in small and medium sized unlisted and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re Offer for Subscription

21 Mar 2024 15:55

RNS Number : 8487H
Maven Income & Growth VCT PLC
21 March 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

Maven Income and Growth VCT PLC (the Company)

Offer for Subscription

21 March 2024

On 13 October 2023, alongside the other Maven VCTs, the Company announced the publication of a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to an offer for subscription of new Ordinary Shares of 10p each (the "Offer").

The Board of the Company is pleased to advise that, with valid subscriptions received to date under the Offer now approaching its initial fundraising target of £5 million, and in view of continued interest from potential investors, the Directors have resolved to make use of the over-allotment facility, as provided for under the terms and conditions of the Offer to the extent required to meet any additional demand.

The deadline for receipt of applications for the Offer is 9.00 am on 5 April 2024 in relation to the tax year 2023/24 and 5.00 pm on 26 April 2024 in relation to the tax year 2024/25. The Offer will close on 1 May 2024 unless it is fully subscribed by an earlier date or extended by the Board to no later than 11 October 2024.

Downloadable versions of the Prospectus documents are available at: mavencp.com/vctoffer.

Any enquiries in respect of the Offer, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

Maven Capital Partners UK LLPSecretary

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

Notes

This announcement does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase, any investment in any jurisdiction, nor shall it (or the fact of its distribution) form the basis of, or be relied on in connection with, any contract therefor.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
STREFLFLZXLEBBZ
Date   Source Headline
26th Apr 20241:33 pmRNSUnaudited NAV & Proposed Final Dividend
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:47 pmRNSIssue of Equity
27th Mar 202410:34 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
21st Mar 20243:55 pmRNSStatement re Offer for Subscription
20th Mar 20243:44 pmRNSUnaudited Net Asset Value
8th Feb 202410:27 amRNSDirector/PDMR Shareholding
8th Feb 202410:26 amRNSDirector/PDMR Shareholding
8th Feb 202410:08 amRNSIssue of Equity
30th Jan 20245:09 pmRNSTransaction in Own Shares
17th Jan 20249:59 amRNSDirector/PDMR Shareholding
17th Jan 20249:57 amRNSIssue of Equity
15th Jan 20244:25 pmRNSUnaudited Net Value Asset
1st Dec 20239:39 amRNSIssue of Equity
24th Nov 202312:04 pmRNSStatement re Dividend Investment Scheme
9th Nov 20233:35 pmRNSResult of General Meeting
19th Oct 20234:51 pmRNSTransaction in Own Shares
18th Oct 20233:54 pmRNSHalf-year Report
13th Oct 20234:56 pmRNSPublication of a Prospectus
5th Oct 20234:39 pmRNSNet Asset Value and Interim Dividend
20th Jul 20234:32 pmRNSTransaction in Own Shares
14th Jul 20239:26 amRNSIssue of Equity
7th Jul 20234:17 pmRNSStatement re Dividend Investment Scheme
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.